YU40794A - Novi sulfonilaminopirimidini - Google Patents

Novi sulfonilaminopirimidini

Info

Publication number
YU40794A
YU40794A YU40794A YU40794A YU40794A YU 40794 A YU40794 A YU 40794A YU 40794 A YU40794 A YU 40794A YU 40794 A YU40794 A YU 40794A YU 40794 A YU40794 A YU 40794A
Authority
YU
Yugoslavia
Prior art keywords
sulfonylaminopyrimidines
new
prophylaxis
medicines
compounds
Prior art date
Application number
YU40794A
Other languages
English (en)
Inventor
V. Breu
K. Burri
J.M. Cassai
M. Clozel
G. Hirth
B.M. Loffler
M. Muller
W. Neidhart
H. Ramuz
Original Assignee
F. Hoffmann - La Roche Ag.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann - La Roche Ag. filed Critical F. Hoffmann - La Roche Ag.
Publication of YU40794A publication Critical patent/YU40794A/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/69—Benzenesulfonamido-pyrimidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

NOVI SULFONILAMINOPIRIMIDINI - Pronalazak se odnosi na nove sulfonuaminopiridine opšte formule u kojoj: R'-R3 svaki nezavisno je vodonik, niži alkil supstituisan i nesupstituisan, niži alkoksi supstituisan i nesupstituisan, niži alkiltio, niži alkenil, halogen, karboksi, amino ili ostatak (Rc, Rd)N-C(0)(CH2)M-ili (Rc, Rd)N-C(0)(CH2)o4; R2 i R3 zajedno i R6 zajedno sa R3 i R7 su butadeinil, meulen-dioksi, etilendioksi ili izopropilidendioksi; R4 je vodonik, niži alkil supstituisan i nesupstituisan, niži alkoksi supstituisan i nesupstituisan, niži alkiltio supstituisan i nesupstituisan, aril, ariltio, ariloksi; R3 - R9 svaki nezavisno je vodonik, halogen, niži alkil, niži alkosi, niži alkiltio, niži alkilsulfonil ili niži alkilsulfmil; R" i Rb svaki nezavisno su vodonik, niži alkil, niži alkoksi ili niži alkiltio; Rc i Rd svaki nezavisno je vodonik, niži alkil ili aril ili oba zajedno sa N-atomom na koji su vezani grade 5-7-člani heterociklični ostatak; Y je ostatak -OC(O)NR10Rn, -NHC(O)NR10Rn,-OC(O)OR10 ili -NHC(0)R10; R10 je niži alkil supstituisan ili nesupstituisan, aril ili ostatak (Rc, Rd)N-C(0)CH2)M; R11 je vodonik ili ostatak R10; R10 i R11 zajedno sa N-atomom za koji su vezani grade 5-7-člani heterociklični ostatak; Zje -0-,-S- ili -CH2-, Xje -0-,-S- ili -NH-njeO ili 1 imje 1,2 ili 3.
YU40794A 1993-06-28 1994-06-27 Novi sulfonilaminopirimidini YU40794A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH192493 1993-06-28

Publications (1)

Publication Number Publication Date
YU40794A true YU40794A (sh) 1997-07-31

Family

ID=4221780

Family Applications (1)

Application Number Title Priority Date Filing Date
YU40794A YU40794A (sh) 1993-06-28 1994-06-27 Novi sulfonilaminopirimidini

Country Status (41)

Country Link
US (1) US5541186A (sh)
EP (1) EP0633259B1 (sh)
JP (1) JP2545200B2 (sh)
KR (1) KR100338905B1 (sh)
CN (1) CN1050839C (sh)
AT (1) ATE175669T1 (sh)
AU (1) AU678467B2 (sh)
BG (1) BG61691B1 (sh)
BR (2) BR9402558A (sh)
CA (1) CA2125730C (sh)
CO (1) CO4230230A1 (sh)
CZ (1) CZ287184B6 (sh)
DE (1) DE59407626D1 (sh)
DK (1) DK0633259T3 (sh)
EC (1) ECSP941111A (sh)
ES (1) ES2127850T3 (sh)
FI (1) FI112944B (sh)
GR (1) GR3029874T3 (sh)
HR (1) HRP940370B1 (sh)
HU (2) HUT67636A (sh)
IL (1) IL110089A (sh)
IS (1) IS4185A (sh)
LT (1) LT3723B (sh)
LV (1) LV11175B (sh)
MY (1) MY110871A (sh)
NO (1) NO306403B1 (sh)
NZ (1) NZ260842A (sh)
PE (1) PE56794A1 (sh)
PH (1) PH30688A (sh)
PL (2) PL177031B1 (sh)
RO (1) RO114325B1 (sh)
RU (1) RU2142457C1 (sh)
SG (1) SG43888A1 (sh)
SI (1) SI0633259T1 (sh)
SK (1) SK280736B6 (sh)
SV (1) SV1994000028A (sh)
TW (1) TW394761B (sh)
UA (1) UA40578C2 (sh)
UY (1) UY23797A1 (sh)
YU (1) YU40794A (sh)
ZA (1) ZA944434B (sh)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5514696A (en) * 1992-05-06 1996-05-07 Bristol-Myers Squibb Co. Phenyl sulfonamide endothelin antagonists
US6743783B1 (en) * 1993-12-01 2004-06-01 Marine Polymer Technologies, Inc. Pharmaceutical compositions comprising poly-β-1→4-N-acetylglucosamine
US6063911A (en) * 1993-12-01 2000-05-16 Marine Polymer Technologies, Inc. Methods and compositions for treatment of cell proliferative disorders
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US6268369B1 (en) 1994-11-16 2001-07-31 Synaptic Pharmaceutical Corporation 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines
MX9703518A (es) 1994-11-16 1997-08-30 Synaptic Pharma Corp Dihidropirimidinas y usos de las mismas.
CA2162630C (en) * 1994-11-25 2007-05-01 Volker Breu Sulfonamides
TW313568B (sh) * 1994-12-20 1997-08-21 Hoffmann La Roche
ES2196090T3 (es) 1994-12-28 2003-12-16 Kowa Co Derivados pirimidinicos.
US5780473A (en) * 1995-02-06 1998-07-14 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5760038A (en) * 1995-02-06 1998-06-02 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5573762A (en) * 1995-04-24 1996-11-12 Genentech, Inc. Use of leukemia inhibitory factor specific antibodies and endothelin antagonists for treatment of cardiac hypertrophy
US5739333A (en) * 1995-05-16 1998-04-14 Tanabe Seiyaku Co., Ltd. Sulfonamide derivative and process for preparing the same
US5846990A (en) * 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
ES2210384T3 (es) * 1995-09-06 2004-07-01 Kowa Co. Ltd. Derivados de la pirimidina.
JPH09124620A (ja) 1995-10-11 1997-05-13 Bristol Myers Squibb Co 置換ビフェニルスルホンアミドエンドセリン拮抗剤
CZ260596A3 (en) * 1995-10-12 1997-12-17 Hoffmann La Roche Sulfonamide derivative, process of its preparation and pharmaceutical composition containing thereof
US6228861B1 (en) 1995-11-16 2001-05-08 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
WO1997022595A1 (fr) * 1995-12-20 1997-06-26 Yamanouchi Pharmaceutical Co., Ltd. Derives arylethenesulfonamide et composition de medicaments renfermant ces derives
SG87051A1 (en) 1996-02-20 2002-03-19 Bristol Myers Squibb Co Process for preparing biphenyl isoxazole sulfonamide intermediates
US5856507A (en) * 1997-01-21 1999-01-05 Bristol-Myers Squibb Co. Methods for the preparation of biphenyl isoxazole sulfonamides
US5939446A (en) * 1996-04-09 1999-08-17 Bristol-Myers Squibb Co. Heteroaryl substituted phenyl isoxazole sulfonamide endothelin antagonists
US6172066B1 (en) 1996-05-16 2001-01-09 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
US6245773B1 (en) 1996-05-16 2001-06-12 Synaptic Pharmaceutical Corporation 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines
US5985830A (en) * 1996-09-16 1999-11-16 Dalhousie University Use of IGF-I for the treatment of kidney disorders
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
WO1998033781A1 (en) * 1997-01-30 1998-08-06 Bristol-Myers Squibb Company Method for preventing or treating low renin hypertension by administering an endothelin antagonist
US6274585B1 (en) 1998-12-23 2001-08-14 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
US6680323B2 (en) 1998-12-23 2004-01-20 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
US7566452B1 (en) 1999-05-04 2009-07-28 New York University Cancer treatment with endothelin receptor antagonists
CA2315614C (en) * 1999-07-29 2004-11-02 Pfizer Inc. Pyrazoles
WO2001081338A1 (en) * 2000-04-25 2001-11-01 Actelion Pharmaceuticals Ltd Substituted sulfonylaminopyrimidines
US6720324B2 (en) * 2000-07-05 2004-04-13 Synaptic Pharmaceutical Corporation Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof
MY140724A (en) 2000-07-21 2010-01-15 Actelion Pharmaceuticals Ltd Novel arylethene-sulfonamides
US6670362B2 (en) 2000-09-20 2003-12-30 Pfizer Inc. Pyridazine endothelin antagonists
US7091201B2 (en) 2000-09-25 2006-08-15 Actelion Pharmaceuticals Ltd. Arylalkane-sulfonamides having endothelin-antagonist activity
US6639082B2 (en) 2000-10-17 2003-10-28 Bristol-Myers Squibb Company Methods for the preparation of biphenyl isoxazole sulfonamides
KR100374326B1 (ko) * 2000-11-29 2003-03-03 한국과학기술연구원 6-히드록시-1, 3-디옥신-4-온 고리를 가진인간면역결핍바이러스 프로테아제 억제 화합물 및 그의제조방법
HU229403B1 (en) 2000-12-18 2013-12-30 Actelion Pharmaceuticals Ltd Novel sulfamides and their use as endothelin receptor antagonists
WO2002083650A1 (en) * 2001-04-11 2002-10-24 Actelion Pharmaceuticals Ltd Novel sulfonylamino-pyrimidines
EP1507756B1 (en) 2002-05-24 2015-07-22 Millennium Pharmaceuticals, Inc. Ccr9 inhibitors and methods of use thereof
AU2011218661B2 (en) * 2002-05-24 2012-07-05 Millennium Pharmaceuticals, Inc. CCR9 inhibitors and methods of use thereof
US7227035B2 (en) * 2002-11-18 2007-06-05 Chemocentryx Bis-aryl sulfonamides
JP4611746B2 (ja) * 2002-11-18 2011-01-12 ケモセントリックス， インコーポレイテッド アリールスルホンアミド
US7741519B2 (en) * 2007-04-23 2010-06-22 Chemocentryx, Inc. Bis-aryl sulfonamides
US7420055B2 (en) 2002-11-18 2008-09-02 Chemocentryx, Inc. Aryl sulfonamides
WO2004050640A1 (en) 2002-12-02 2004-06-17 Actelion Pharmaceuticals Ltd Pyrimidine-sulfamides and their use as endothelian receptor antagonist
DE102004027119A1 (de) 2003-06-06 2004-12-30 Schott Ag UV-Strahlung absorbierendes Glas mit geringer Absorption im sichtbaren Bereich, ein Verfahren zu seiner Herstellung sowie dessen Verwendung
PT1725540E (pt) 2004-03-05 2012-11-29 Hoffmann La Roche Diaminopirimidinas como antagonistas de p2x3 e p2x2/3
US7745436B2 (en) * 2004-04-13 2010-06-29 Synta Pharmaceuticals Corporation Disalt inhibitors of IL-12 production
WO2006000371A2 (en) 2004-06-28 2006-01-05 F.Hoffmann-La Roche Ag Pyrimidine derivatives as 11beta-hsd1 inhibitors
KR100847203B1 (ko) * 2004-06-28 2008-07-17 에프. 호프만-라 로슈 아게 피리미딘 유도체
TW200628467A (en) 2004-11-11 2006-08-16 Actelion Pharmaceuticals Ltd Novel sulfamides
EP1924565B1 (en) * 2005-09-01 2016-09-14 F.Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p3x2/3 modulators
JP4850911B2 (ja) * 2005-09-01 2012-01-11 エフ．ホフマン−ラ ロシュ アーゲー Ｐ２ｘ３およびｐ２ｘ２／３モジュレーターとしてのジアミノピリミジン
CA2620129C (en) 2005-09-01 2014-12-23 F. Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p2x2/3 modulators
JP2009530284A (ja) * 2006-03-13 2009-08-27 エンサイシブ・ファーマシューティカルズ・インコーポレイテッド 拡張期心不全を治療するための方法と組成物
JP2009530280A (ja) * 2006-03-13 2009-08-27 エンサイシブ・ファーマシューティカルズ・インコーポレイテッド シタクスセンタンナトリウムの配合物
US20080026061A1 (en) * 2006-06-22 2008-01-31 Reichwein John F Crystalline N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4.5-(methylenedioxy)phenylacetyl]-thiophene-3-sulfonamide
AR062501A1 (es) 2006-08-29 2008-11-12 Actelion Pharmaceuticals Ltd Composiciones terapeuticas
NZ616957A (en) 2007-02-19 2015-06-26 Marinepolymer Tech Inc Hemostatic compositions and therapeutic regimens
MX2010001837A (es) 2007-08-17 2010-03-10 Actelion Pharmaceuticals Ltd Derivados de 4-pirimidinasulfamida.
AU2011239466B2 (en) 2010-04-15 2015-01-22 Marine Polymer Technologies, Inc. Anti-bacterial applications of poly -N-acetylglucosamine nanofibers
NZ732118A (en) 2011-04-15 2018-11-30 Marine Polymer Tech Inc Treatment of disease with poly-n-acetylglucosamine nanofibers
RU2604060C1 (ru) * 2015-10-06 2016-12-10 федеральное государственное бюджетное образовательное учреждение высшего образования "Санкт-Петербургская государственная химико-фармацевтическая академия" Министерства здравоохранения Российской Федерации (ФГБОУ ВО СПХФА Минздрава России) Способ получения 2,5-дизамещенных 6-гидроксипиримидин-4(3н)-онов
SG11201808220VA (en) 2016-03-22 2018-10-30 Merck Sharp & Dohme Allosteric modulators of nicotinic acetylcholine receptors
RU2643356C2 (ru) * 2016-06-22 2018-02-01 федеральное государственное бюджетное образовательное учреждение высшего образования "Волгоградский государственный медицинский университет" Министерства здравоохранения Российской Федерации Новое n-арилсульфамидное производное о-бензоиламинобензойной кислоты, обладающее анксиолитической, актопротекторной и антидепрессивной активностью

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0210526B1 (de) 1985-07-24 1989-05-24 Siemens Aktiengesellschaft Kernreaktorbrennelement
TW270116B (sh) 1991-04-25 1996-02-11 Hoffmann La Roche
RU2086544C1 (ru) 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
TW287160B (sh) * 1992-12-10 1996-10-01 Hoffmann La Roche

Also Published As

Publication number Publication date
LV11175B (en) 1996-06-20
BG98880A (bg) 1995-05-31
ZA944434B (en) 1995-01-03
PL304007A1 (en) 1995-01-09
LV11175A (lv) 1996-04-20
NO942428L (no) 1994-12-29
HRP940370B1 (en) 1999-12-31
HRP940370A2 (en) 1996-12-31
DE59407626D1 (de) 1999-02-25
FI943084A0 (fi) 1994-06-27
CA2125730C (en) 2005-10-18
CZ287184B6 (en) 2000-10-11
HU9401907D0 (en) 1994-09-28
RU2142457C1 (ru) 1999-12-10
JPH0717972A (ja) 1995-01-20
PE56794A1 (es) 1995-02-07
UA40578C2 (uk) 2001-08-15
TW394761B (en) 2000-06-21
LT3723B (en) 1996-02-26
CN1106007A (zh) 1995-08-02
CO4230230A1 (es) 1995-10-19
SK77994A3 (en) 1995-03-08
NO942428D0 (no) 1994-06-27
GR3029874T3 (en) 1999-07-30
NO306403B1 (no) 1999-11-01
US5541186A (en) 1996-07-30
DK0633259T3 (da) 1999-09-06
JP2545200B2 (ja) 1996-10-16
ECSP941111A (es) 1994-11-16
IL110089A0 (en) 1994-10-07
SG43888A1 (en) 1997-11-14
PH30688A (en) 1997-09-16
FI112944B (fi) 2004-02-13
ES2127850T3 (es) 1999-05-01
EP0633259B1 (de) 1999-01-13
ATE175669T1 (de) 1999-01-15
NZ260842A (en) 1996-05-28
SI0633259T1 (en) 1999-06-30
IL110089A (en) 2000-08-31
SK280736B6 (sk) 2000-07-11
PL177031B1 (pl) 1999-09-30
CA2125730A1 (en) 1994-12-29
EP0633259A1 (de) 1995-01-11
MY110871A (en) 1999-05-31
BG61691B1 (bg) 1998-03-31
RU94022258A (ru) 1996-04-20
BR9402558A (pt) 1995-03-28
HUT67636A (en) 1995-04-28
PL175771B1 (pl) 1999-02-26
KR950000676A (ko) 1995-01-03
AU6594894A (en) 1995-01-05
BR1100089A (pt) 2000-03-14
CZ157394A3 (en) 1995-01-18
FI943084A (fi) 1994-12-29
LTIP1979A (en) 1995-01-31
AU678467B2 (en) 1997-05-29
CN1050839C (zh) 2000-03-29
KR100338905B1 (ko) 2002-11-13
IS4185A (is) 1994-12-29
RO114325B1 (ro) 1999-03-30
HU211533A9 (en) 1995-12-28
SV1994000028A (es) 1995-04-19
UY23797A1 (es) 1994-12-16

Similar Documents

Publication Publication Date Title
YU40794A (sh) Novi sulfonilaminopirimidini
TW287160B (sh)
IE892272L (en) Novel fused heterocyclic compounds
EP0562049A4 (en) Novel 4-arylpiperazines and 4-arylpiperidines
TW207533B (sh)
DK0731801T3 (da) Substituerede aminoaylkylaminopyridiner
IT1262952B (it) Tetraalchilpiperidine, loro preparazione e loro impiego come stabilizzanti alla luce. (caso 153-5502)